Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Clear cell renal cell carcinoma (ccRCC) frequently involves von Hippel-Lindau (VHL) gene inactivation and cell cycle gene alterations.
• Understanding the genetic basis of ccRCC is crucial for developing effective treatments.

Purpose of the Study:

• To create a genetically accurate mouse model of ccRCC.
• To investigate the role of primary cilia in ccRCC development.
• To evaluate therapeutic strategies for ccRCC.

Main Methods:

• Deletion of Vhl, Trp53, and Rb1 genes in mouse renal epithelial cells to induce ccRCC.
• Comparative analysis of molecular markers and mRNA expression profiles between mouse and human ccRCC.
• Exome sequencing to identify recurrent mutations.
• Testing standard ccRCC therapies and acriflavine (HIF-α inhibitor) on the mouse model.

Main Results:

• The mouse model successfully developed ccRCC from proximal tubule cells, mirroring human ccRCC.
• Recurrent mutations in primary cilia-related genes were found in both mouse and human ccRCC, suggesting genetic ciliopathies.
• Tumor responses to therapies varied, similar to human clinical behavior.
• Acriflavine showed therapeutic effects in some tumors, indicating potential for HIF-α inhibition.

Conclusions:

• The developed mouse model is a valuable tool for studying ccRCC biology.
• A subset of ccRCCs may be classified as genetic ciliopathies.
• HIF-α inhibition presents a promising therapeutic avenue for ccRCC treatment.